B I O Q U O T E S
“
“ To fuel India ' s transition from generics to biosimilar drugs , two key aspects are at play : genuine innovation and biosimilars . The biosimilars are instrumental in cost reduction within global healthcare systems , paving the way for reinvestment in newer technologies and enhanced patient care .”
75
BioVoiceNews | May / June 2024